Combining Cisplatin and Mitomycin with Radiotherapy in Anal Carcinoma

摘要: The European Organization for Research and Treatment of Cancer (EORTC) phase II study No. 22953 demonstrated the feasibility reducing overall treatment time chemoradiation, delivering mitomycin C twice rather than once fluorouracil during whole treatment. We tested chemoradiation in anal carcinoma with cisplatin a study. Twenty-one patients locally advanced (15 women, 6 men) were treated. first sequence radiotherapy consisted 36 Gy over four weeks. After gap interval 16 days, second was given, 23.4 2.5 weeks. Mitomycin delivered at 10 mg/m2 day 1 each 25 mg/m2/week sequence. compliance rates radiation, mitomycinm, cispaltin (dose timing) 100 percent. median duration 16 days (14–30 days). mitomycin, 100, 76.2, 85.7 percent, respectively. Grade ≥ 2 acute toxicities 62, 29, 25, 5 percent observed skin, diarrhea, hematologic, renal toxicities, Nineteen complete response (90.5 percent). Combining radiation cancer is feasible. results are promising. EORTC currently comparing this combination 5-fluorouracil large II–III trial.